Antiinflammatory Therapy Reduced CVD Risk
A randomized, double-blind trial of canakinumab targeting interleukin-1β innate immunity pathway revealed a significantly lower rate of recurrent cardiovascular events in patients of myocardial infarction (MI). The trial included 10,061 patients with previous MI and a high-sensitivity C-reactive protein （hsCRP） level of 2 mg or more per liter. Canakinumab (at […]